



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms

Federica Raucci^{a,1}, Adel Abo Mansour^{b,c,1}, Gian Marco Casillo^a, Anella Saviano^a,
 Francesco Caso^d, Raffaele Scarpa^d, Nicola Mascolo^a, Asif Jilani Iqbal^{b,a,*}, Francesco Maione^{a,*}

^a ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy

^b Institute of Cardiovascular Sciences (ICVS), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK

^c Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Guraiger, Abha 62529, Saudi Arabia

^d Rheumatology Research Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, via S. Pansini 5, 80131 Naples, Italy

ARTICLE INFO

Keywords:

COVID-19
 IL-17A
 Platelet
 Thrombus
 Vascular diseases

1. Introduction

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome (SARS) which first appeared in Wuhan, China, December 2019, and has since spread globally [1]. To date, official figures released by World Health Organization (WHO), indicate over 3 million cases worldwide with over 200,000 deaths. However, the number of newly diagnosed patients has started to decline, suggesting that the rate of transmission is beginning to be controlled by countries [2]. Although most patients have mild symptoms and good prognosis after infection, some develop severe symptoms and die due to multiple organ failure [3–5]. Based on the published literature and clinical observations, researchers and clinicians around the world have postulated about the pathogenesis of this viral infection in humans. We know that the virus has the capacity to cross mucous membranes (especially nasal and larynx mucosa), and in severe cases leads to multiple systemic manifestations and pneumonia requiring mechanical ventilation [6].

Interestingly, COVID-19 disease prognosis is strongly correlated to

clinical characteristics of patients, with high risk associated to those with a concomitance of cardiovascular risk factors, primarily obesity, hypertension, and diabetes mellitus [4,7]. In the context of COVID-19-associated cardiovascular manifestations, more recent studies report that the disease is commonly complicated with coagulopathy linked to disseminated intravascular coagulation (DIC) and/or thrombotic and thromboembolic disease [4,8,9]. For these reasons, many patients with severe COVID-19 meet the Third International Consensus Definitions for Sepsis (SEPSIS-3) [10].

Moreover, we must consider that the development of thrombotic and thromboembolic disease could be a direct consequence of the systemic inflammatory process related to interleukin (IL)-6 and IL-17A up-regulation [11–14]. This clinical scenario has prompted the use of intravenous immunoglobulin (IVIG) and low molecular weight heparin (LMWH) anticoagulant therapy as early as possible, particularly when circulating T and B cells numbers decrease, and inflammatory cytokines and D-Dimer (a non-specific parameter of thrombi formation) increase abnormally [15–17]. While IVIG has shown efficacy in the treatment of patients with influenza and SARS, more clinical data is required, for

Abbreviations: COVID-19, Coronavirus disease 2019; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; EC, endothelial cells; ERK-2, extracellular signal regulated kinase-2; HUVECs, human umbilical vein endothelial cells; IL-, interleukin-; IVIG, intravenous immunoglobulin; LMWH, low molecular weight heparin; SARS, severe acute respiratory syndrome; SEPSIS-3, Third International Consensus Definitions for Sepsis; TF, tissue factor; Th-, T-helper; TNF- α , tumor necrosis factor- α ; WHO, World Health Organization.

* Corresponding authors.

E-mail addresses: A.J.Iqbal@bham.ac.uk (A.J. Iqbal), francesco.maione@unina.it (F. Maione).

¹ These authors share first co-authorship.

<https://doi.org/10.1016/j.autrev.2020.102572>

Received 23 April 2020; Accepted 25 April 2020

Available online 03 May 2020

1568-9972/ © 2020 Elsevier B.V. All rights reserved.




Fig. 1. Schematic representation of inflammatory pathways (left part) involved in the COVID-19-related respiratory syndrome. The inflammatory scenario induced by COVID-19 has cardiovascular implications (right part, top panel) in terms of Th-1/Th-17/T-reg balance that favors the production of IL-17A. The overproduction of this cytokine (right part, bottom panel) amplifies platelet hyper-reactivity and thrombus formation.

both IVIG and LMWH, to confirm significant efficacy in COVID-19 patients [18–20].

2. IL-17A and COVID-19-related thrombotic and vascular mechanisms

Viral infection and subsequent systemic and/or local inflammation is a common cause of DIC [21–23] due to increased synthesis of cytokines such as tumor necrosis factor- α (TNF- α), IL-1 β , IL-6, IL-17A and IL-18 [24].

IL-17A (commonly known as IL-17) is the most studied member of the IL-17 cytokine family. It is produced by T-helper (Th)-17 lymphocytes, and by innate cellular components [25,26]. This “unique” pro-inflammatory cytokine, highly produced and modulated in patients with chronic inflammatory-based diseases, also plays a role in the cardiovascular system, more specifically, it is involved in cardiovascular complications associated with autoimmune and inflammatory-based diseases [27].

Indeed, in the attempt to find a link between inflammatory markers and endothelial dysfunction, Marder et al., [28] demonstrated that elevated IL-17A levels strongly correlated with vascular dysfunction in subjects affected by rheumatoid arthritis. Furthermore, it has been shown that, human umbilical vein endothelial cells (HUVECs), treated with IL-17A, synergistically with TNF- α , induces tissue factor (TF) expression and modulates thrombomodulin [29] and thrombosis formation [30,31].

In addition to IL-17A role on the vascular endothelium, data, from our research group and others has also highlighted a role for this cytokine in platelet biology. We previously reported IL-17A ability to

increase, in both mouse and human, platelet activation [32] and to modulate, *in vivo*, arterial thrombus formation [33] through the extracellular signal-regulated kinase-2 (ERK-2) signaling pathway [34]. Moreover, a study from Ding et al., [35] investigated the role of IL-17A in mouse and human deep vein thrombosis (DVT) formation, and found that this cytokine promotes DVT pathogenesis by enhancing platelet activation/aggregation, neutrophil infiltration, and endothelial cell (EC) activation. Collectively, these data suggest that the use of an anti-IL-17A neutralising monoclonal antibody may be useful for DVT-related syndromes.

3. Discussion

Taking all these various pieces of evidence (albeit minimal), we would like to hypothesize that in COVID-19 patients, IL-17A could potentially promote a pro-thrombotic state in the vascular system. Indeed, the increased level of this cytokine in COVID-19 infection would not be, *per se*, a stimulus for thrombogenesis but, most likely, support platelet aggregate formation at sites of vascular injury (Fig. 1). Based on these assumptions, it would be fascinating to characterize IL-17 levels in bronchoalveolar lavage fluid (BALF) and plasma/serum samples of mild- and severe-infected COVID-19 patients, and potentially go on to test the efficacy of antibodies targeting IL-17A (alone or in a sequential therapy with anti-IL-6 agents) for the treatment of thrombotic, as well respiratory and systemic manifestations of severe COVID-19. These could be useful not only for new therapeutic strategies but also for improving our understanding of the etiopathogenesis and genetic susceptibility of COVID-19 infection.

Author contributions

FR, AAM, GMC and AS drafted the manuscript. FC, RS, NM, AJI and FM wrote and revised the manuscript. All Authors gave final approval to the publication.

Declaration of Competing Interest

This article has been conducted and written in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was in part supported by MIUR (PRIN 2017; 2017A95NCJ/2017A95NCJ_002, "Stolen molecules - Stealing natural products from the depot and reselling them as new drug candidates"). AJI is supported by Birmingham Fellowship and AAM by a Saudi Government/KKU scholarship.

References

- Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qin Hai M, Yongxia S, et al. Exerts antiviral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). *Pharmacol Res* 2020;104761. <https://doi.org/10.1016/j.phrs.2020.104761>.
- World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 73. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_4;_2020 [Accessed 14 April 2020].
- Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. *Int. J. Oral Sci.* 2020;12. 10.1038%2Fs41368-020-0075-9.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395:507–13. [https://doi.org/10.1016/s0140-6736\(20\)30211-7](https://doi.org/10.1016/s0140-6736(20)30211-7).
- Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. *Autoimmun Rev* 2020;102538. <https://doi.org/10.1016/j.autrev.2020.102538>.
- Rivellese F, Prediletto E. ACE2 at the Centre of COVID-19 from paucisymptomatic infections to severe pneumonia. *Autoimmun Rev* 2020;102536. <https://doi.org/10.1016/j.autrev.2020.102536>.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395(10229):1054–62. doi:[https://doi.org/10.1016/s0140-6736\(20\)30566-3](https://doi.org/10.1016/s0140-6736(20)30566-3) Epub 2020 Mar 11. Erratum in: *Lancet*. 2020 Mar 28;395(10229):1038. *Lancet*. 2020 Mar 28;395(10229):1038.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497–506. [https://doi.org/10.1016/s0140-6736\(20\)30183-5](https://doi.org/10.1016/s0140-6736(20)30183-5).
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020;18(4):844–7. <https://doi.org/10.1111/jth.14768>.
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3). *JAMA* 2016;315(8):801–10. <https://doi.org/10.1001/jama.2016.0287>.
- Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? *Autoimmun Rev* 2020;19(5):102524. <https://doi.org/10.1016/j.autrev.2020.102524>.
- McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. *Autoimmun Rev* 2020;102537. <https://doi.org/10.1016/j.autrev.2020.102537>.
- Feng Y, Yu M, Zhu F, Zhang S, Ding P, Wang M. IL-9 promotes the development of deep venous thrombosis by facilitating platelet function. *Thromb Haemost* 2018;118(11):1885–94. <https://doi.org/10.1055/s-0038-1673614>.
- Casillo GM, Mansour AA, Raucci F, Saviano A, Mascolo N, Iqbal AJ, et al. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome? This paper is dedicated to Sofia Maione born during COVID-19 outbreak. *Pharmacol Res* 2020;104791. <https://doi.org/10.1016/j.phrs.2020.104791>.
- Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *J Thromb Haemost* 2020. <https://doi.org/10.1111/jth.14854>.
- Alger HM, Williams Iv JH, Walchok JG, Bolles MM, Fonarow GC, Rutan C. The role of data registries in the time of COVID-19. *Circ Cardiovasc Qual Outcomes* 2020. <https://doi.org/10.1161/circoutcomes.120.006766>.
- Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. *JACC Basic Transl Sci* 2020. <https://doi.org/10.1016/j.jacbs.2020.04.002>.
- Thachil J. The versatile heparin in COVID-19. *J Thromb Haemost* 2020. <https://doi.org/10.1111/jth.14821>.
- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. *Am J Hematol* 2020. <https://doi.org/10.1002/ajh.25829>.
- Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. *J Thromb Thrombolysis* 2020. <https://doi.org/10.1007/s11239-020-02105-8>.
- Samad F, Ruf W. Inflammation, obesity, and thrombosis. *Blood* 2013;122(20):3415–22. <https://doi.org/10.1182/blood-2013-05-427708>.
- Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. *Blood* 2014; 123(18):2759–67. doi:10.1182%2Fblood-2013-11-462432.
- Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. *Blood* 2019;133(9):906–18. <https://doi.org/10.1182/blood-2018-11-882993>.
- Masters SL, Simon A, Aksentjevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). *Annu. Rev. Immunol.* 2009; 27:621–68. doi:10.1146%2Fannurev.immunol.25.022106.141627.
- D'Acquisto F, Maione F, Pederzoli-Ribeil M. From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead? *Biochem Pharmacol* 2010;79(4):525–34. <https://doi.org/10.1016/j.bcp.2009.09.015>.
- Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. *Immunity* 2011;34(2):149–62. <https://doi.org/10.1016/j.immuni.2011.02.012>.
- Maione F. Commentary: IL-17 in chronic inflammation: from discovery to targeting. *Front Pharmacol* 2016;7:250. <https://doi.org/10.3389/fphar.2016.00250>.
- Marde W, Khalatbari S, Myles JD, Hench R, Yalavarthi S, Lustig S, et al. 17 as a novel predictor of vascular function in rheumatoid arthritis. *Ann. Rheum. Dis.* 2011; 70(9):1550–5. doi:10.1136%2Fard.2010.148031.
- Hot A, Lenief V, Miossec P. Combination of IL-17 and TNF α induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. *Ann Rheum Dis* 2012;71(5):768–76. <https://doi.org/10.1136/annrheumdis-2011-200468>.
- Bouchnita A, Miossec P, Tosenberger A, Volpert V. Modeling of the effects of IL-17 and TNF- α on endothelial cells and thrombus growth. *C R Biol* 2017;340(11–12):456–73. <https://doi.org/10.1016/j.crv.2017.10.002>.
- de Boer OJ, Li X, Teeling P, Mackaay C, Ploegmakers HJ, van der Loos CM, et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. *Thromb Haemost* 2013;109(2):290–7. <https://doi.org/10.1160/th12-06-0425>.
- Maione F, Cicala C, Liverani E, Mascolo N, Perretti M, D'Acquisto F. IL-17A increases ADP-induced platelet aggregation. *Biochem Biophys Res Commun* 2011;408(4):658–62. <https://doi.org/10.1016/j.bbrc.2011.04.080>.
- Maione F, Parisi A, Caiazza E, Morello S, D'Acquisto F, Mascolo N, et al. Interleukin-17A exacerbates ferric chloride-induced arterial thrombosis in rat carotid artery. *Int J Inflamm* 2014. <https://doi.org/10.1155/2014/247503>.
- Zhang S, Yuan J, Yu M, Fan H, Guo ZQ, Yang R, et al. IL-17A facilitates platelet function through the ERK2 signaling pathway in patients with acute coronary syndrome. *PLoS One* 2012;7(7):e40641. <https://doi.org/10.1371/journal.pone.0040641>.
- Ding P, Zhang S, Yu M, Feng Y, Long Q, Yang H, et al. IL-17A promotes the formation of deep vein thrombosis in a mouse model. *Int Immunopharmacol* 2018;57:132–8. <https://doi.org/10.1016/j.intimp.2018.02.006>.